Marex Group stock price target raised to $55 by TD Cowen on earnings outlook

Published 14/08/2025, 16:46
Marex Group stock price target raised to $55 by TD Cowen on earnings outlook

Investing.com - TD Cowen has raised its price target on Marex Group PLC (NASDAQ:MRX) to $55.00 from $54.00 while maintaining a Buy rating on the stock. The new target represents significant upside from the current price of $36.26, with InvestingPro data showing the stock has already delivered an impressive 50.5% return over the past year.

The price target adjustment follows Marex’s second-quarter results released on August 13, with TD Cowen indicating that consensus estimates are "materially underestimating" the company’s long-term earnings potential, remaining approximately 10% too low for 2025-2026 estimates. The company’s strong fundamentals are reflected in its robust 38.5% revenue growth and healthy P/E ratio of 10.4x.

TD Cowen noted that Marex management addressed recent short seller concerns during their earnings presentation, which should help clarify the company’s business model for investors, while client reaction has been "stable/improving."

The research firm identified three potential drivers for Marex shares: reduced short seller efficacy, upward revisions to consensus estimates, and business model durability.

The new $55 price target represents 13 times TD Cowen’s revised 2026 earnings per share estimate for Marex Group.

In other recent news, Marex reported strong financial results for the second quarter of 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $1.02, which was higher than the projected $0.93, resulting in a 9.68% surprise. Revenue also exceeded forecasts, reaching $500 million compared to the anticipated $470.53 million, marking a 6.28% increase. These results highlight Marex’s robust performance in the quarter. The earnings announcement did not significantly affect the company’s stock price. These developments are of interest to investors monitoring the company’s financial health and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.